Stem cells can regenerate my damaged discs

What Patients Say

My doctor says my discs are degenerating. I read that stem cells can regrow damaged tissue. If I have an intradiscal stem cell injection before things get worse, I can avoid surgery.

Where Did This Come From?

The logic is seductive and almost makes sense. You have degenerating tissue. Scientists can grow tissue in a lab. Therefore, injecting regenerative cells into your disc should rebuild it.

The problem is not the logic. The problem is that a disc is one of the most biologically hostile environments in the human body for regeneration — and most clinics selling you this treatment have not solved that problem.

Here is what the science actually says. The intervertebral disc has almost no blood supply. It is largely avascular, which means cells survive through a slow diffusion process rather than through the rich blood flow that helps other tissues heal. It sits under continuous mechanical load. Its internal environment, as degeneration progresses, becomes progressively acidic and enzyme-rich — a chemical environment that is destructive to cells, including injected ones. And perhaps most importantly: no one has yet demonstrated that injecting cells into a human disc reliably restores disc height, reverses structural degeneration, or produces durable pain relief in a well-designed, controlled clinical trial.

The FDA makes the regulatory position explicit: regenerative medicine therapies have not been approved for the treatment of any orthopaedic condition, including disc disease, back pain, or neck pain. Products marketed for these uses — including stem cells, bone marrow aspirate concentrate (BMAC), stromal vascular fraction (fat-derived cells), umbilical cord cells, and exosomes — require FDA approval to be legally marketed, and none currently hold that approval for spinal indications.

"Same-day stem cell" procedures — where cells are harvested and re-injected within the same visit — are specifically regulated because the processing steps involved typically mean the product qualifies as a drug under FDA rules, requiring approval that these clinics do not have.

There is a further distinction patients rarely hear. An MRI showing disc improvement is not the same as pain improvement. Several small case series have reported modest changes in disc signal or hydration on follow-up MRI after biological injections. Whether those imaging changes translate to meaningful clinical benefit — reduced pain, improved function, avoided surgery — has not been established in adequately powered randomised controlled trials.

Research in this space is genuinely active and some of it is promising. Early-phase intradiscal PRP and mesenchymal stem cell trials show signals worth investigating further. But early-phase signals and approved treatments are separated by years of rigorous testing — for good reason.

The Verdict

For current routine clinical use. The biology is genuinely interesting. The commercial product is ahead of the evidence.

What To Do Instead

• If you have significant disc degeneration causing symptoms, pursue a proper clinical evaluation first — many patients are much better candidates for physiotherapy, targeted injections, or surgery than for experimental biologics
• If you want to contribute to advancing the science, ask your spine specialist about registered clinical trials — real research that follows safety rules and gathers data properly
• Ask any regenerative medicine provider for their IND application number, outcome registry data, and published peer-reviewed results on patients like you
• Be specifically sceptical of "same-day" procedures, cash-pay-only practices, and clinics that cannot name their cell source, processing protocol, or cell count delivered

← Back to all myths